Acute Heart Failure - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Heart Failure - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Heart Failure - Pipeline Review, H1 2015', provides an overview of the Acute Heart Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acute Heart Failure Overview 7
Therapeutics Development 8
Pipeline Products for Acute Heart Failure - Overview 8
Pipeline Products for Acute Heart Failure - Comparative Analysis 9
Acute Heart Failure - Therapeutics under Development by Companies 10
Acute Heart Failure - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Acute Heart Failure - Products under Development by Companies 15
Acute Heart Failure - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Anexon, Inc. 17
Angion Biomedica Corp. 18
Bayer AG 19
Lee's Pharmaceutical Holdings Limited 20
Novartis AG 21
Nyken BV 22
Ono Pharmaceutical Co., Ltd. 23
PhaseBio Pharmaceuticals, Inc. 24
Trevena, Inc. 25
Acute Heart Failure - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ANG-4011 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ANX-042 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BR-5489 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
cenderitide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
istaroxime - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NYK-1112 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
omecamtiv mecarbil - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ONO-4232 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PB-1046 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
serelaxin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TRV-027 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TRV-120023 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ularitide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Acute Heart Failure - Recent Pipeline Updates 56
Acute Heart Failure - Dormant Projects 68
Acute Heart Failure - Discontinued Products 69
Acute Heart Failure - Product Development Milestones 70
Featured News & Press Releases 70
Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 70
Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 70
Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027 71
May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 72
May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting 72
May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 73
Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 74
Mar 25, 2014: FDA Staff Says Novartis' Serelaxin Shouldn't Be Approved 74
Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion 75
Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Number of Products under Development for Acute Heart Failure, H1 2015 8
Number of Products under Development for Acute Heart Failure - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Acute Heart Failure - Pipeline by Amgen Inc., H1 2015 16
Acute Heart Failure - Pipeline by Anexon, Inc., H1 2015 17
Acute Heart Failure - Pipeline by Angion Biomedica Corp., H1 2015 18
Acute Heart Failure - Pipeline by Bayer AG, H1 2015 19
Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 20
Acute Heart Failure - Pipeline by Novartis AG, H1 2015 21
Acute Heart Failure - Pipeline by Nyken BV, H1 2015 22
Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 23
Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 24
Acute Heart Failure - Pipeline by Trevena, Inc., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Acute Heart Failure Therapeutics - Recent Pipeline Updates, H1 2015 56
Acute Heart Failure - Dormant Projects, H1 2015 68
Acute Heart Failure - Discontinued Products, H1 2015 69